AC
ANRO icon

Almitas Capital’s Alto Neuroscience ANRO Stock Holding History

Almitas Capital’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-78,520
Closed -$1.77M – 146
2026
Q1 		$1.77M Hold
78,520
– – 0.4% 49
2025
Q4 		$1.4M Sell
78,520
-116,625
-60% -$1.47M 0.31% 50
2025
Q3 		$784K Hold
195,145
– – 0.18% 50
2025
Q2 		$429K Sell
195,145
-39,241
-17% -$93.4K 0.11% 64
2025
Q1 		$506K Sell
234,386
-32,526
-12% -$116K 0.17% 60
2024
Q4 		$1.13M Buy
+266,912
New +$1.67M 0.25% 53

Other funds holding ANRO

AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Almitas Capital's ANRO Position: Q2 2026 in Review

Almitas Capital sold out of Alto Neuroscience (ANRO) in Q2 2026, closing a stake of 78,520 shares — an estimated $1.77M sold.

Almitas Capital first reported a position in ANRO in Q4 2024 and held it in 6 quarters. The position peaked at $1.77M in Q1 2026. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

  • Almitas Capital reported no remaining Alto Neuroscience position as of Q2 2026 after selling out during the quarter.
  • Almitas Capital sold 78,520 Alto Neuroscience shares in Q2 2026, an estimated $1.77M.
  • Almitas Capital first reported a position in Alto Neuroscience in Q4 2024 and held it in 6 quarters.
  • Almitas Capital's Alto Neuroscience position peaked at $1.77M in Q1 2026.
  • 114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Almitas Capital's 13F filing for Q2 2026, filed 17 Aug 2026.